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Abstract 
Experimental studies have revealed that phytoestrogens may modulate the risk of certain sites of cancer due to their 
structural similarity to 17β-estradiol. The present study investigates whether intake of these compounds may 
influence prostate cancer risk in human populations. During a median follow up of 11.5 years, 2,598 cases of 
prostate cancer (including 287 advanced cases) have been identified among 27,004 men in the intervention arm of 
the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Dietary intake of phytoestrogens (excluding 
lignans) was assessed with a food frequency questionnaire. Cox proportional hazards regression analysis was 
performed to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for dietary isoflavones and coumestrol 
in relation to prostate cancer risk. After adjustment for confounders, an increased risk of advanced prostate cancer 
[HR (95% CI) for quintile (Q) 5 vs. Q1] was found for the dietary intake of total isoflavones [1.91 (1.25-2.92)], 
genistein [1.51 (1.02-2.22), daidzein [1.80 (1.18-2.75), and glycitein [1.67 (1.15- 2.43)] (p-trend for all associations 
≤0.05). For example, HR (95% CI) for comparing the Q2, Q3, Q4, and Q5 with Q1 of daidzein intake was 1.45 
(0.93-2.25), 1.65 (1.07-2.54), 1.73 (1.13-2.66), and 1.80 (1.18-2.75), respectively (p-trend: 0.013). No statistically 
significant associations were observed between the intake of total isoflavones and individual phytoestrogens and 
non-advanced and total prostate cancer after adjustment for confounders. This study revealed that dietary intake of 
isoflavones was associated with an elevated risk of advanced prostate cancer.   
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INTRODUCTION 
Prostate cancer is one of the most common cancers in Western countries and its incidence has been rapidly 
increasing in Asian countries during the last several decades [1, 2]. Age, ethnicity, and family history are the only 
established, but non-modifiable, risk factors for this malignancy [3]. Although migrant and temporal trend studies 
suggest that diet may play a role in prostate cancer etiology [2], few specific nutrients that appear to alter its 
occurrence have been identified.   
Phytoestrogens are a family of estrogen-like bioactive compounds found in plants [4]. Individual 
phytoestrogens derived from dietary sources are classified into three major categories: isoflavones (e.g. genistein, 
daidzein, glycitein, formononetin, and biochanin A), lignans (e.g. matairesinol and seco-isolariciresinol), and 
coumestans (e.g. coumestrol) [5]. While the main food sources of isoflavones are soybeans, kudzu root, American 
groundnuts, those of lignans are flaxseed, green tea, and strawberries. Coumestans are abundant in legumes, clover, 
and soybean sprouts [6]. Experimental studies have revealed that phytoestrogen intake may modulate the risk of 
certain types of cancer [7] due to their structural similarity to 17β-estradiol [8] and the resulting competitive binding 
to estrogen receptors [9]. Of particular relevance to prostate carcinogenesis is that rats fed a phytoestrogen-rich diet 
experienced a reduction in serum testosterone concentrations [10]. Given that high serum testosterone was observed 
to be a risk factor for prostate cancer in some, although not all, epidemiologic studies [11, 12], these animal studies 
suggest that high intake of phytoestrogens may be associated with a reduced risk of this disease. Conversely, another 
study in mice showed that genistein enhances the proliferation and metastasis of prostate cancer cells derived from 
human surgical samples, suggesting that phytoestrogens may play a role in the development of aggressive prostate 
tumor [13]. 
Despite biological plausibility, it still remains unknown whether phytoestrogen intake may influence prostate 
cancer risk in human populations. A few studies examining this association produced mixed results [14-16]. 
Phytoestrogen intake is lower and has a smaller between-person variation in Western countries than in East Asia 
countries (e.g. China and Japan) [17, 18]. However, reported significant, inverse association of adolescent 
phytoestrogen intake with postmenopausal breast cancer in Canadian women [19] suggests that variations in 
phytoestrogen intake among individuals in Western countries are sufficient for investigators to examine the effects 
of these bioactive compounds on human health and disease. To date, few prospective cohort studies have evaluated 
whether phytoestrogen intake is associated with the occurrence of total and advanced prostate cancers in a large 
sample of the U.S. population [16].  Therefore, the present study investigates this hypothesis using data previously 
collected from participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). 
SUBJECTS AND METHODS 
Study Population 
Approximately 155,000 men and women were enrolled to the PLCO from 10 screening centers across the U.S. 
between November 1993 and July 2001. In the present study, only men (n=76,683) were considered because the 
outcome of interest was prostate cancer. Subjects were excluded if they did not complete the baseline questionnaire 
(n=892), were not asked to complete the Dietary Questionnaire (DQX) at baseline (n=38,343, all enrolled to the 
control arm), completed the DQX but determined to be invalid [eight or more missing responses, extreme energy 
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intakes (top or bottom 1%), or missing the DQX completion date)] (n=6,594), had a history of cancer (n=705), or 
were not followed up after the enrollment (n=52). Subjects who were outliers for total isoflavone intake (defined as 
value that falls above the sum of third quartile and twice the interquartile range) were also excluded (n = 2,287). 
Finally, cases of prostate cancer diagnosed within two years of enrollment into the study were excluded to eliminate 
preclinical disease at baseline (n = 806). After all above exclusions, a total of 27,004 men in the PLCO met the 
eligibility criteria of the present study. As control arm participants were not offered a food frequency questionnaire 
(FFQ) (i.e. the Dietary Questionnaire), all subjects included in the present analysis were in the intervention arm. 
Men in the intervention arm were offered annual prostate-specific antigen (PSA) blood test and digital rectal 
exam (DRE) for screening prostate cancer during their first 6 years of participation in the trial and follow-up 
continued for at least 7 additional years. A positive test is considered to be either a PSA test >4 ng/mL or one of the 
following signs from a DRE: nodularity, induration, asymmetry, or a loss of anatomic landmarks. Participants with a 
positive screening result received a subsequent diagnostic evaluation (e.g. prostate biopsy). During a median follow 
up of 11.5 years, 2,598 cases of prostate cancer (including 287 advanced cases) have been identified from the 27,004 
eligible men. Advanced prostate cancer cases were defined as patients who were diagnosed with stage II (Gleason 
score of ≥8), stage III, or stage IV of the disease, or died from it [20].  
Data Collection 
PLCO participants in the intervention arm were asked to complete a sex-specific baseline questionnaire and the 
FFQ mentioned above. The vast majority (96.8%) of the PLCO participants completed the baseline questionnaire 
that solicits information on age, race, body mass index (BMI, kg/m2), marital status, education level, physical 
activity, cigarette smoking, family history of prostate and other cancers, aspirin use, ibuprofen use, and personal 
history of vasectomy [20]. 
The FFQ was offered to the participants in the intervention arm at the time of randomization into the PLCO. 
The FFQ is a 137-item food frequency questionnaire developed to assess usual diet and alcohol consumption during 
the past year, and this dietary assessment instrument has not been specifically validated for isoflavones. It also 
contained questions on use of vitamins and other dietary supplements. Dietary intake of energy and nutrients were 
calculated by multiplying the amount of energy and nutrients in a standard portion size of each food item by the 
reported frequency of consumption and summing over all food items. Individual phytoestrogens considered for this 
study included genistein, daidzein, glycitein, formononetin, biochanin A, and coumestrol. These six individual 
phytoestrogens represent all kinds of the phytoestrogens with data available from the PLCO. Dietary intake of 
lignans was not estimated from the FFQs completed by PLCO participants because lignan values are not available 
from the USDA food composition database. Dietary intake of total isoflavones was calculated by summing each of 
the five individual isoflavones examined. The nutrient contents of food items were based on values from the USDA 
Database for the Isoflavone Content of Selected Foods (Release 2.0) (that also contains data on coumestrol) [21] and 
other two national dietary databases, the USDA’s 1994-96 Continuing Survey of Food Intakes by Individuals and 
the University of Minnesota’s Nutrition Data Systems for Research [20]. 
Statistical Analysis 
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Demographic, anthropometric, and lifestyle characteristics of subjects were compared across the quintiles of 
total isoflavone intake using chi-square tests for categorical variables and analysis of variance for continuous 
variables. As intakes of individual phytoestrogens were not normally distributed, the Wilcoxon rank-sum test was 
employed to compare their differences between subjects who developed any or advanced prostate cancer and those 
who were free from this malignancy during the specified follow-up period.  
Cox proportional hazards regression analysis was conducted to calculate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for prostate cancer risk in relation to dietary intake of isoflavones and coumestrol. The 
follow-up period for each individual started from the date of cohort entry to date of diagnosis with prostate cancer, 
death, study dropout, or the censor date (December 31, 2009), whichever came earlier. The date of cohort entry was 
defined as the date of randomization, baseline questionnaire completion, or dietary survey completion, whichever 
occurred later. Dietary intake of total isoflavones, each individual isoflavone, and coumestrol were divided into 
quintiles based on the entire sample, and the HRs for quintiles 2 through 5 were calculated with the lowest quintile 
as referent category. Covariates included in the final models were age (years), race (non-Hispanic White, non-
Hispanic Black, Asian, and other), BMI (kg/m2) (continuous), smoking status (never smoker, former smoker, and 
current smoker), alcohol intake (drinkers, non-drinkers), and family history of prostate cancer (yes, no). Other 
variables evaluated as potential confounders were education, marital status, physical activity, family history of other 
cancer, aspirin use, ibuprofen use, vasectomy, as well as intake of energy, iron, processed meats, red meat, and 
caffeine. None of those variables were included in the final models because they were not significantly associated 
with prostate cancer risk or did not materially alter risk estimates (<10%). Potential interactions of dietary 
isoflavones and coumestrol with age, race, BMI, education, smoking status, alcohol intake, caffeine intake, red meat 
intake, and family history of prostate cancer on prostate cancer risk were tested. None of the interaction terms 
examined were statistically significant and were thus not included in the final models. 
All above analyses were conducted separately for advanced, non-advanced, and total prostate cancer because 
epidemiologic studies suggest that aggressive prostate cancer has a different etiology from indolent disease and is 
the outcome that is clinically important [22]. Linear trends across quintiles of isoflavone and coumestrol intake were 
examined using the median in each quintile to create a continuous variable and entering it into regression models. 
All constructed models were graphically checked for the proportional hazards assumption, and none of the models 
was found to violate the assumption. SPSS version 23 (Armonk, NY) was used for statistical analysis. A p-value of 
<0.05 (2-sided) was considered statistically significant.  
RESULTS 
Characteristics of study subjects are shown in Table 1. Statistically significant differences existed in age, race, 
BMI, education, smoking status, alcohol intake, red meat intake, and family history of prostate cancer across total 
isoflavone quintiles. Subjects in the highest quintile of total isoflavone intake were more likely to be Asian, better 
educated, never smokers, and have a slightly lower BMI than those in other quintiles. 
For the PLCO participants included in the present study, the top three food contributors to intake of total 
isoflavones were tofu/soybeans (66.9%), peas (10.8%), and tea (10.3%), and the corresponding three food 
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items/groups contributing most to intake of coumestrol were tea (52.1%), beans (37.7%), and other soups (not 
vegetable and tomato soups) (8.7%) (data not shown). 
The median intake of total and individual isoflavones and coumestrol were compared between total prostate 
cancer cases, advanced cases, and those who had not developed prostate cancer through the censor date (December 
31, 2009) (Table 2). Subjects who were diagnosed with advanced prostate cancer had a significantly higher median 
intake of total isoflavones, genistein, daidzein, glycitein, formononetin, and biochanin A than those who were not 
diagnosed with prostate cancer during follow-up (all p ≤0.044). Similar differences between total prostate cancer 
and non-cases were found for total isoflavones, genistein, daidzein, and glycitein (all p ≤0.043).  
HRs (95% CIs) for each of three prostate cancer outcomes considered in relation to dietary intake of total and 
individual isoflavones and coumestrol are presented in Table 3. After adjustment for confounders, HR (95% CI) of 
advanced prostate cancer for comparing quintile 5 with quintile 1 of dietary intake of total isoflavones, genistein, 
daidzein, and glycitein were 1.91 (1.25-2.92) (p-trend: 0.007), 1.51 (1.02-2.22) (p-trend: 0.012), 1.80 (1.18-2.75) (p-
trend: 0.013), and 1.67 (1.15-2.43) (p-trend: 0.003), respectively. As indicated by significant p-trend values, the risk 
of advanced prostate cancer increased monotonically with increasing intake of genistein, daidzein, and glycitein, 
although the strength of the associations were generally modest over the whole range of their dietary intake. For 
example, HR (95% CI) for quintiles 2 to 5 compared with quintile 1 of daidzein intake was 1.45 (0.93-2.25), 1.65 
(1.07-2.54), 1.73 (1.13-2.66), and 1.80 (1.18-2.75), respectively. No statistically significant associations were 
observed between the intake of total isoflavones and individual phytoestrogens and non-advanced and total prostate 
cancer after adjustment for confounders.  
A separate Cox proportional hazards regression analysis that included the 2287 outliers of total isoflavones was 
also carried out. The results obtained were largely similar to those of the analysis that excluded those outliers, 
whereas the associations of advanced prostate cancer with intake of total and individual isoflavones were overall 
stronger and more significant for linear trends across quintiles in the latter analysis. A sensitivity analysis that 
included the 806 cases of prostate cancer diagnosed within the first two years of enrollment showed weaker, less 
significant but still positive associations between intake of individual isoflavones and the risk of advanced prostate 
cancer. Similar results were obtained when intakes of total and individual isoflavones were evaluated as continuous 
variables. For example, HRs (95% CIs) of advanced prostate cancer per an interquartile range increase in intakes of 
total isoflavone, genistein, daidzein, and glycitein were 1.25 (1.07-1.47), 1.21 (1.03-1.43), 1.22 (1.06-1.39), and 1.18 
(1.05-1.32), respectively.  In addition, the results of this nutrient-based analysis were largely confirmed by food-
based analysis. Specifically, subjects who were in the highest quintile of dietary intake of soy products experienced 
a significantly increased risk of advanced prostate cancer as compared with those in the lowest quintile of intake 
[RR (95% CI): 1.64 (1.11, 2.43)].  
DISCUSSION 
In this prospective cohort study, we found a significant positive association of dietary intake of total 
isoflavones, genistein, daidzein, and glycitein with the risk of advanced prostate cancer. All these associations were 
independent of established or suspected risk factors for prostate cancer. 
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Genistein is one of the most extensively investigated phytoestrogens. The present study showed that dietary 
intake of genistein was significantly associated with an elevated risk of advanced prostate cancer. Previous studies 
have reported an inverse association between plasma concentrations of genistein and the risk of prostate cancer [23, 
24]. Some experimental studies have also revealed a protective effect of genistein on prostate cancer [25, 26], 
although total phytoestrogens may be more effective than genistein alone for inhibiting the proliferation of prostate 
cancer [27]. It is possible that an inverse association between genistein intake and prostate cancer is in part ascribed 
to its effect of lowering serum testosterone concentrations, which was found in rats fed a phytoestrogen-rich diet 
[10]. We were not able to examine the potential role of serum testosterone in the association between isoflavone 
intake and prostate cancer as data on this androgenic hormone are not available from the PLCO.  
Recently, however, an experimental study suggested that genistein promoted the proliferation and metastasis of 
patient-derived prostate cancer cells by increasing phosphorylation of epidermal growth factor receptors and its 
downstream molecules [13]. In that study, a prostatectomy sample was grafted into mice, and it is found that lymph 
node and secondary organ metastases were significantly increased in genistein-treated mice compared with untreated 
controls. In addition, genistein-treated mice had more proliferating and fewer apoptotic cancer cells than untreated 
mice, resulting in an enhanced tumorigenic activity [13]. This animal study offered some biological plausibility for 
our present observation that dietary intake of genistein was positively associated with the risk of advanced prostate 
cancer. To our knowledge, this potential adverse effect has not been reported in other epidemiologic studies, which 
might have arisen from two main reasons. First, most previous studies have investigated Asian populations that 
ingested higher amounts of phytoestrogens than Western populations. Second, few epidemiologic studies on this 
research topic have presented separate results for total and advanced prostate cancer [28], a distinction substantially 
relevant to the etiology, prevention, and treatment of the disease. 
Some other biological mechanisms are available for the increased risk of advanced prostate cancer associated 
with intake of genistein and other individual isoflavones. As stated previously, phytoestrogens may induce 
estrogenic responses in the body due to their structural similarity to 17β-estradiol [8]. It has been proposed that 
estrogen is implicated in prostate carcinogenesis through its genotoxic metabolites and regulation of estrogen 
receptor-β (ERβ) expression during prostate tumor progression [29]. Moreover, the Prostate Cancer Prevention Trial 
(PCPT) showed that some repeat polymorphisms in genes involved in estrogen synthesis and metabolism were 
associated with a more than two-fold increased risk of aggressive prostate cancer (Gleason score ≥7). Of note, the 
most pronounced promoting effect on advanced prostate cancer was observed in PCPT patients who were treated 
with finasteride, a medication that inhibits the conversion of testosterone to dihydrotestosterone, leading to elevated 
concentrations of estrogen [30]. Therefore, it is reasonable to infer that an increased risk of advanced prostate cancer 
related to higher intake of isoflavones was likely mediated through increased estrogenic activity. Nevertheless, 
precise mechanisms for the effects of isoflavones on prostate cancer and particularly its advanced phenotype merit 
further investigation as it has been found that isoflavones have both estrogenic and anti-estrogenic functions [31]. 
Like genistein, daidzein, one of the main isoflavones found in soy products, has also been widely investigated in 
relation to the risk of cancer and other diseases [32]. The present study did not find a significant association of 
dietary daidzein intake with both non-advanced and total prostate cancer, an observation in agreement with the 
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results of several studies in which dietary intake of phytoestrogens was assessed or plasma or urinary concentrations 
of their biomarkers were measured among European or Jamaican residents [24, 28]. Similarly, two double-blind, 
placebo-controlled randomized controlled trials showed that daidzein supplementation was not significantly 
associated with a decreased risk of prostate cancer [33, 34]. Our results of an increased risk of advanced prostate 
cancer in relation to dietary intake of daidzein have not been reported previously. As both daidzein and genistein are 
the isoflavones that are abundant in soy products and some other commonly consumed food items, it is biologically 
plausible that daidzein may also confer an elevated risk of advanced prostate cancer due to its estrogenic effect on 
the prostate gland.  
Prostate cancer can be broadly classified into slow-growing indolent and fast-growing aggressive tumors, and 
most advanced or metastatic prostate cancers are derived from the latter category. A major strength of the present 
study is that its large sample size permitted the performance of separate analyses for these two distinct types of 
tumor in relation to intake of isoflavones and coumestrol. Our study revealed that the effect of isoflavones differs by 
the biological behavior of prostate tumor. However, this differential effect has seldom been investigated in 
epidemiologic studies due to small sample sizes (n<250 prostate cancer cases in most studies) [28, 35]. Although it 
remains to be further investigated whether phytoestrogens exert a differential effect on indolent and aggressive 
prostate cancers, our results provide additional evidence supporting that these two types of the disease have different 
etiologies. It is possible that this differential effect of isoflavones is in part ascribed to differences of indolent and 
aggressive prostate tumors in their expression levels of estrogen receptors. It has been found that the expression of 
ERα was increased but that of ERβ was reduced in aggressive, androgen-refractory prostate cancer compared with 
its indolent phenotype [36]. Ample experimental evidence supports that ERβ possesses antiproliferative and even 
tumor-suppressive properties [36]. Therefore, the competitive binding of increased intake of isoflavones that have a 
weak estrogenic effect with endogenous estrogen to ERβ in the context of its reduced expression in early aggressive 
prostate tumor may promote the progression of this type of tumor to screening-detectable or clinically-diagnosable 
disease. However, lack of data on the expression of estrogen receptors from the PLCO precludes us from examining 
this possibility. 
Another major advantage of the present study is that the prospective nature of the PLCO largely excluded the 
possibility of reverse causality between intake of total and individual isoflavones and the risk of prostate cancer, a 
bias that is not uncommon in case-control studies, particularly those measuring exposure biomarkers in biological 
samples. This reverse causality might still exist to some extent in prospective cohort studies due to the presence of 
preclinical prostate cancer at baseline. However, the results presented in this paper were obtained after excluding 
cases of prostate cancer diagnosed with two years of enrollment. 
Several limitations of the present study should be considered when interpreting the results obtained. Although 
dietary intake of total isoflavones, individual isoflavones, and coumestrol was estimated using a food frequency 
questionnaire modified from the validated Willet and Block FFQs [37], it is well known that recall errors often occur 
in questionnaire-based dietary assessment. Such dietary measurement errors, if non-differential, could result in an 
attenuation of the strength of the associations of interest. Thus, the associations found in this study may be 
conservative. In addition, dietary intake of total isoflavones, individual isoflavones, and/or coumestrol may be 
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underestimated due to inadequate coverage of all food items containing phytoestrogens in most available food 
composition databases. For example, soy additives are found in some processed foods [38], and certain isoflavones 
are naturally present in lower concentrations in commonly consumed foods such as vegetables [39], fruits, and nuts 
[40]. Therefore, it is possible that the isoflavones from these food products are underrepresented in the food 
composition databases and the actual impact of isoflavones on prostate cancer risk was thus not observed. The 
findings of the present study were based on a single dietary assessment. Thereby, it is also possible that some study 
subjects had changed their dietary habits during follow-up, which might have somewhat distorted our reported 
effects of isoflavone intake on prostate cancer risk. Another limitation of using a dietary questionnaire to assess 
phytoestrogen nutritional status is that this method is unable to capture phytoestrogen metabolites (e.g. equol, O-
desmethylangolensin) produced by intestinal bacteria [41]. Circulating or urinary biomarkers of phytoestrogens are 
free from recall bias, are an integrated reflection of phytoestrogens from both food sources and bacteria synthesis, 
and account for individual differences in the absorption and metabolism of these chemical compounds. Although 
some studies have shown that phytoestrogen biomarkers are only modestly correlated with their dietary intake [42, 
43], it would be preferable to measure dietary exposure to phytoestrogen using both dietary questionnaire and 
biomarkers in the same populations to better evaluate its effect on prostate cancer risk. However, data on 
phytoestrogen biomarkers are not available from the PLCO at this time. The FFQ used in the PLCO has not been 
specifically validated for isoflavones. It is thus possible that some subjects were misclassified with regard to their 
dietary intake of isoflavones, which could have led to a further attenuation of the associations examined that is 
ascribed to recall bias in dietary assessment. Taken together, the positive results obtained in the present study based 
on dietary intake data warrant replication from epidemiological studies using a FFQ specifically validated for this 
class of nutrients and/or analyzing their circulating biomarkers. One more limitation of our study is lack of data on 
dietary intake of lignans for the reasons mentioned above. As lignans substantially contribute to total phytoestrogen 
intake in Western diets, inability to investigate the effect of lignan intake on prostate cancer risk has somewhat 
weakened the impact of the present study. Finally, the exclusion of men in the control arm who were not asked to 
complete a food frequency questionnaire should have not substantially reduced the generalizability of our obtained 
results as men in the intervention arm and the control arm were overall comparable with regard to demographic, 
anthropometric, socioeconomic, and lifestyle factors due to the successful implementation of randomization in the 
PLCO [44]. 
A question may arise as to whether the observed dietary intake of isoflavones and coumestrol in the present 
study is biologically meaningful. Intake of total isoflavones among our study subjects (median: 0.42 mg/day) is 
largely comparable to that of studies conducted in other Western populations, e.g. 0.36  mg/day (median) for Dutch 
women [45] but much lower than that of studies carried out among Asian populations, e.g. 36 mg/day (mean) for 
Shanghai men [46]. Intake of phytoestrogens or their biomarkers have been associated with an altered risk of 
colorectal cancer [47] and cardiovascular disease [48] and reduced concentrations of C-reactive protein [49] among 
residents of North America. It is unknown what blood or urinary concentrations of phytoestrogens for PLCO 
subjects were in response to the dietary intake of these nutrients due to lack of biomarker data. However, the median 
urinary levels of isoflavones were reported to be 160 ng/mL among U.S. men and women in the continuous National 
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Health and Nutrition Examination Survey, 1999–2004 (about the same time period as for the PLCO) [48]. It is 
apparent that phytoestrogen concentrations in blood and urine among individuals with a typical Western diet are 
generally far lower than those achieved in most intervention studies with a common isoflavone supplementation 
dose of 30 mg/day or greater [48, 50]. 
The present study shows that higher intake of total isoflavones, genistein, daidzein, and glycitein were 
associated with an increased risk of advanced prostate cancer. The findings of the present study need to be 
confirmed in more prospective cohort or nested case-control studies to be conducted by measuring both dietary 
intake of phytoestrogens and their biomarkers among populations with diverse dietary habits. A thorough 
understanding of the role of phytoestrogens in prostate cancer etiology is expected to offer innovative practical 
avenues for the primary prevention of this disease.  
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Table 1. Baseline characteristics of study subjects by quintiles (Q) of dietary intake of total isoflavone intake in 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), 1993-2009 
 Total Isoflavones (mg/day)  
Characteristics 
Q1 (0.0-0.17) Q2 (0.18-0.31) Q3 (0.32-0.48) Q4 (0.49-0.74) Q5 (0.75-2.03)   
n = 5,405 n = 5,415 n = 5,384 n = 5,410 n = 5,390 p-value 
Age [Mean (SD)] 61.6 (5.3) 61.9 (5.2) 63.7 (5.1) 63.6 (5.3) 62.5 (5.1) <0.001* 
Race/Ethnicity (%)             
     Non-Hispanic White 19.8 20.2 20.2 20.1 19.7 <0.001* 
     Non-Hispanic Black 26.7 19.0 21.1 18.9 14.4   
     Asian 3.0 5.9 5.9 19.0 66.2   
     Other   23.8 21.3 14.3 17.8 22.8   
BMI [Mean (SD)] 27.8 (4.2) 27.9 (4.2) 27.7 (4.1) 27.5 (4.1) 27.6 (4.1) <0.001* 
Education (%)             
     Less than High School 23.0 21.6 23.1 18.1 14.3 <0.001* 
     High School Graduate or Equivalent 24.4 23.3 21.0 17.3 14.0   
     Post High School Education 20.7 20.6 20.1 19.8 18.6   
     College Graduate or Higher 16.8 17.8 18.6 21.9 24..9   
Smoking Status (%)             
     Never Smoker 17.7 18.9 20.1 21.0 22.3 <0.001* 
     Former Smoker 26.6 23.3 19.2 16.0 14.9   
     Current Smoker 20.3 20.1 19.9 20.2 19.4   
Alcohol Intake (%)             
     Do Not Drink Alcohol 25.2 24.1 16.1 14.7 19.9 <0.001* 
     Drinks Alcohol 18.9 19.2 20.8 21.2 20.0   
Total Energy Intake (kcal/day) [Mean (SD)] 1927 (696) 2338 (776) 2328 (849) 2388 (835) 2630 (875) <0.001* 
Caffeine Intake (mg/day) [Mean (SD)] 558 (664) 585 (665) 544 (648) 543 (630) 570 (611) 0.002* 
Red Meat Intake (g/day) [Mean (SD)] 39.6 (34.4) 47.1 (38.7) 43.8 (38.8) 40.1 (36.7) 44.7 (41.4) <0.001* 
Family History of Prostate Cancer             
     Yes 17.7 19.6 21.4 21.6 19.6 0.026* 
     No 20.1 20.2 19.7 20.0 20.1   
*Significant value 
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Table 2. Differences in dietary intake of total and individual isoflavones and coumestrol (mg/day) between subjects 
who did and did not develop prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
(PLCO)a, 1993-2009 
Phytoestrogens 
Total Prostate 
Cancer (1) 
(n = 2,598) 
Advanced Prostate 
Cancer (2) 
(n = 287) 
Non-Prostate 
Cancer (3)  
(n = 24,406) 
p-value:  
(1) vs. (3) 
p-value: 
(2) vs. (3) 
Total Isoflavones 0.420 (0.211 - 0.699) 0.476 (0.257 - 0.733) 0.392 (0.194 - 0.682) 0.002* <0.001* 
Genistein 0.169 (0.050 - 0.318) 0.191 (0.058 - 0.340) 0.152 (0.046 - 0.315) 0.043* 0.001* 
Daidzein 0.245 (0.143 - 0.372) 0.272 (0.178 - 0.399) 0.231 (0.131 - 0.361) 0.001* <0.001* 
Glycitein 0.005 (0.002 - 0.017) 0.014 (0.002 - 0.026) 0.004 (0.002 - 0.016) 0.001* <0.001* 
Formononetin 0.011 (0.007 - 0.018) 0.012 (0.007 - 0.019) 0.011 (0.006 - 0.018) 0.515 0.044* 
Biochanin A 0.050 (0.032 - 0.077) 0.053 (0.036 - 0.080) 0.049 (0.031 - 0.075) 0.138 0.008* 
Coumestrol 0.077 (0.038 - 0.150) 0.089 (0.041 - 0.160) 0.079 (0.039 - 0.153) 0.555 0.325 
a Values are medians (the interquartile range) 
*Significant value 
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Table 3 HRs (95% CIs) for advanced, non-advanced, and total prostate cancer according to quintiles (Q) of intakes of total and individual isoflavones and coumestrol in the Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), 1993-2009 
  Advanced Prostate Cancer Non-advanced Prostate Cancer All Prostate Cancer 
 
No. of 
Cases 
Person- 
Years 
Crude HR 
(95% CI) 
Adjusted HR 
(95% CI)a 
No. of 
Cases 
Person- 
Years 
Crude HR  
(95% CI) 
Adjusted HR 
(95% CI)a 
No. of 
Cases 
Person- 
Years 
Crude HR  
(95% CI) 
Adjusted HR 
(95% CI)a Phytoestrogens 
(mg/day) 
Total Isoflavones                         
Q1 (0.0 - 0.17) 33 2,094 Reference Reference 438 27,088 Reference Reference 471 29,182 Reference Reference 
Q2 (0.18 - 0.31) 54 3,366 1.60 (1.04 - 2.47)* 1.56 (1.00 - 2.42)* 440 27,289 0.99 (0.87 - 1.13) 0.97 (0.85 - 1.11) 494 30,655 1.03 (0.91 - 1.17) 1.02 (0.89 - 1.16) 
Q3 (0.32 - 0.48) 58 3,777 1.68 (1.10 - 2.58)* 1.49 (0.96 - 2.30) 475 30,397 1.07 (0.94 - 1.21) 1.01 (0.88 - 1.15) 533 34,174 1.11 (0.98 - 1.26) 1.04 (0.91 - 1.18) 
Q4 (0.49 - 0.74) 72 4,682 2.06 (1.37 - 3.11)* 1.70 (1.11 - 2.61)* 485 30,807 1.08 (0.95 - 1.23) 1.01 (0.88 - 1.15) 557 35,489 1.15 (1.01 - 1.30)* 1.06 (0.93 - 1.20) 
Q5 (0.75 - 2.03) 70 4,535 2.07 (1.37 - 3.13)* 1.91 (1.25 - 2.92)* 473 29,798 1.07 (0.94 - 1.22) 1.02 (0.90 - 1.17) 543 34,333 1.14 (1.01 - 1.29)* 1.09 (0.96 - 1.23) 
p-trend     0.001* 0.007*     0.183 0.560     0.018* 0.151 
Genistein                         
Q1 (0.0 - 0.04) 45 2,915 Reference Reference 461 28,699 Reference Reference 506 31,614 Reference Reference 
Q2 (0.05 - 0.09) 47 2,900 1.07 (0.71 - 1.60) 1.03 (0.68 - 1.58) 433 26,762 0.96 (0.84 - 1.09) 0.96 (0.84 - 1.09) 480 29,662 0.97 (0.86 - 1.10) 0.96 (0.85 - 1.09) 
Q3 (0.10 - 0.19) 56 3,608 1.22 (0.82 - 1.80) 1.13 (0.75 - 1.69) 470 29,921 1.02 (0.90 - 1.16) 0.96 (0.84 - 1.09) 526 33,529 1.04 (0.92 - 1.17) 0.97 (0.86 - 1.10) 
Q4 (0.20 - 0.34) 70 4,492 1.51 (1.04 - 2.19)* 1.31 (0.89 - 1.94) 504 32,336 1.09 (0.96 - 1.24) 1.02 (0.90 - 1.17) 574 36,828 1.13 (1.00 - 1.27) 1.05 (0.92 - 1.19) 
Q5 (0.35 - 1.12) 69 4,539 1.53 (1.05 - 2.23)* 1.51 (1.02 - 2.22)* 443 27,661 0.97 (0.85 - 1.11) 0.94 (0.82 - 1.08) 512 32,200 1.02 (0.90 - 1.16) 0.99 (0.87 - 1.13) 
p-trend     0.006* 0.012*     0.829 0.716     0.264 0.64 
Daidzein                         
Q1 (0.0 - 0.11) 45 2,087 Reference Reference 461 26,675 Reference Reference 464 28,762 Reference Reference 
Q2 (0.12 - 0.19) 47 3,365 1.54 (1.00 - 2.38) 1.45 (0.93 - 2.25) 433 28,870 1.04 (0.91 - 1.19) 1.00 (0.87 - 1.14) 514 32,235 1.08 (0.95 - 1.22) 1.03 (0.91 - 1.17) 
Q3 (0.20 - 0.28) 56 4,117 1.87 (1.23 - 2.85)* 1.65 (1.07 - 2.54)* 470 29,756 1.08 (0.94 - 1.23) 1.02 (0.89 - 1.17) 533 33,873 1.13 (1.00 - 1.28) 1.07 (0.94 - 1.21) 
Q4 (0.29 - 0.40) 70 4,272 1.91 (1.26 - 2.91)* 1.73 (1.13 - 2.66)* 504 29,948 1.08 (0.94 - 1.23) 1.01 (0.88 - 1.15) 540 34,220 1.14 (1.00 - 1.29)* 1.06 (0.93 - 1.20) 
Q5 (0.41 - 1.64) 69 4,613 2.08 (1.37 - 3.14)* 1.80 (1.18 - 2.75)* 443 30,130 1.09 (0.95 - 1.24) 1.03 (0.90 - 1.18) 547 34,743 1.16 (1.02 - 1.31)* 1.09 (0.96 - 1.23) 
p-trend     0.001* 0.013*     0.222 0.637     0.025* 0.208 
Glycitein                         
Q1 (0.0 - 0.001) 50 3,165 Reference Reference 505 31,418 Reference Reference 555 34,583 Reference Reference 
Q2 (0.002 - 0.003) 54 3,398 1.02 (0.70 - 1.50) 1.07 (0.72 - 1.58) 516 31,886 0.98 (0.86 - 1.10) 1.00 (0.88 - 1.14) 570 35,284 0.98 (0.87 - 1.10) 1.01 (0.90 - 1.14) 
Q3 (0.004 - 0.014) 61 3,936 1.32 (0.91 - 1.92) 1.23 (0.83 - 1.80) 462 29,526 1.02 (0.90 - 1.16) 0.98 (0.86 - 1.12) 523 33,462 1.05 (0.93 - 1.18) 1.00 (0.88 - 1.13) 
Q4 (0.015 - 0.026) 53 3,490 1.53 (1.04 - 2.25)* 1.25 (0.83 - 1.88) 396 25,783 1.19 (1.04 - 1.36)* 1.10 (0.96 - 1.27) 449 29,273 1.22 (1.08 - 1.38)* 1.11 (0.98 - 1.27) 
Q5 (0.027 - 0.090) 69 4,465 1.64 (1.14 - 2.35)* 1.67 (1.15 - 2.43)* 432 26,766 1.03 (0.90 - 1.17) 1.02 (0.89 - 1.16) 501 31,231 1.08 (0.96 - 1.22) 1.08 (0.95 - 1.22) 
p-trend     0.001* 0.003*     0.184 0.449     0.020* 0.095 
Formononetin                         
Q1 (0.0 - 0.005) 42 2,655 Reference Reference 472 29,566 Reference Reference 514 32,221 Reference Reference 
Q2 (0.006 - 0.009) 59 3,806 1.34 (0.90 - 1.99) 1.30 (0.87 - 1.96) 499 31,228 1.01 (0.89 - 1.15) 1.01 (0.89 - 1.15) 558 35,034 1.04 (0.92 - 1.17) 1.03 (0.91 - 1.17) 
Q3 (0.010 - 0.013) 62 3,955 1.45 (0.98 - 2.15) 1.47 (0.99 - 2.19) 440 27,544 0.92 (0.81 - 1.05) 0.92 (0.80 - 1.05) 502 31,499 0.97 (0.85 - 1.09) 0.96 (0.85 - 1.09) 
Q4 (0.014 - 0.021) 67 4,327 1.54 (1.05 - 2.27)* 1.50 (1.01 - 2.22)* 460 29,139 0.95 (0.83 - 1.08) 0.91 (0.80 - 1.04) 527 33,466 1.00 (0.88 - 1.13) 0.96 (0.85 - 1.09) 
Q5 (0.022 - 0.170) 57 3,711 1.46 (0.98 - 2.17) 1.42 (0.95 - 2.13) 440 27,902 1.00 (0.88 - 1.14) 0.98 (0.85 - 1.11) 497 31,613 1.04 (0.92 - 1.18) 1.01 (0.89 - 1.15) 
p-trend     0.139 0.192     0.990 0.593     0.615 0.944 
             
Biochanin A                         
Q1 (0.0 - 0.028) 45 2,916 Reference Reference 461 28,783 Reference Reference 506 31,699 Reference Reference 
19 
 
Q2 (0.029 - 0.041) 51 3,285 1.10 (0.74 - 1.64) 1.03 (0.69 - 1.54) 465 29,155 0.98 (0.86 - 1.12) 0.97 (0.85 - 1.11) 516 32,440 0.99 (0.88 - 1.12) 0.98 (0.86 - 1.11) 
Q3 (0.042 - 0.057) 61 3,895 1.29 (0.88 - 1.90) 1.17 (0.79 - 1.73) 462 29,024 0.96 (0.85 - 1.10) 0.95 (0.83 - 1.08) 523 32,919 0.99 (0.88 - 1..12) 0.97 (0.85 - 1.10) 
Q4 (0.058 - 0.086) 66 4,266 1.47 (1.01 - 2.15)* 1.39 (0.95 - 2.03) 451 28,470 0.99 (0.87 - 1.13) 0.95 (0.84 - 1.09) 517 32,736 1.03 (0.92 - 1.17) 0.99 (0.88 - 1.13) 
Q5 (0.087 - 0.360) 64 4,092 1.45 (0.99 - 2.13) 1.26 (0.85 - 1.85) 472 29,947 1.05 (0.92 - 1.19) 1.01 (0.88 - 1.15) 536 34,039 1.09 (0.96 - 1.23) 1.03 (0.91 - 1.17) 
p-trend     0.030* 0.146     0.328 0.773     0.100 0.451 
Coumestrol                         
Q1 (0.0 - 0.03) 50 3,252 Reference Reference 488 30,672 Reference Reference 538 33,924 Reference Reference 
Q2 (0.04 - 0.06) 55 3,484 1.13 (0.77 - 1.65) 1.16 (0.79 - 1.72) 453 28,418 0.95 (0.84 - 1.09) 0.94 (0.82 - 1.07) 508 31,902 0.97 (0.86 - 1.10) 0.96 (0.85 - 1.09) 
Q3 (0.07 - 0.10) 65 4,216 1.32 (0.92 - 1.91) 1.30 (0.89 - 1.90) 478 29,812 1.00 (0.88 - 1.13) 0.98 (0.86 - 1.11) 543 34,028 1.03 (0.91 - 1.16) 1.01 (0.89 - 1.14) 
Q4 (0.11 - 0.19) 58 3,671 1.19 (0.82 - 1.74) 1.22 (0.83 - 1.79) 450 28,591 0.95 (0.83 - 1.08) 0.93 (0.81 - 1.06) 508 32,262 0.97 (0.86 - 1.10) 0.95 (0.84 - 1.08) 
Q5 (0.20 - 1.27) 59 3,831 1.24 (0.85 - 1.81) 1.25 (0.85 - 1.84) 442 27,886 0.95 (0.83 - 1.08) 0.94 (0.83 - 1.08) 501 31,717 0.97 (0.86 - 1.10) 0.97 (0.86 - 1.10) 
p-trend     0.441 0.438     0.435 0.502     0.631 0.706 
a Adjusted for age, race/ethnicity, BMI, smoking status, alcohol intake, and family history of prostate cancer. 
*Significant value 
 
 
 
 
 
